Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma

Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease. This business is the pharmaceuticals division of Japanese conglomerate Mitsubishi Chemical Group. The post Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma…

Read More

5 Key Facts about Medicaid Coverage for People with Disabilities

This brief considers options under consideration to cut Medicaid spending by $2.3 trillion over ten years and their potential impact on people with disabilities. Policy changes such as per capita caps, reduced federal funding for the ACA expansion, and Medicaid work requirements could require states to limit coverage, reduce benefits, or cut provider payments. Given…

Read More

Navigating the Build vs. Buy Debate for Member Engagement Solutions

The evolving landscape of healthcare demands that health plans continuously refine their engagement strategies, making this decision more critical than ever. Plan leaders must consider key factors, including cost, speed, scalability, and effectiveness, to guide them toward the most impactful approach. The post Navigating the Build vs. Buy Debate for Member Engagement Solutions appeared first…

Read More